# Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

> **NCT01149720** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 24 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Tivantinib (ARQ 197) Capsule
- **DRUG:** Tivantinib (ARQ 197) Tablet
- **DRUG:** Tivantinib (ARQ 197) Capsule D, oral

## Key facts

- **NCT ID:** NCT01149720
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2019-02-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01149720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01149720, "Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01149720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*